Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05111509 · ClinicalTrials.gov registry record · Early Phase 1
A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent
A Early Phase 1 study of Neuroendocrine Tumor Grade 2 and Neuroendocrine Tumor Grade 1, sponsored by Yusuf Menda.
- Active
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05111509 is a Early Phase 1 study of Neuroendocrine Tumor Grade 2 and Neuroendocrine Tumor Grade 1 that is active but no longer recruiting, run by Yusuf Menda. The registered enrollment target is 20 participants, below the 71-participant average among 3 other Neuroendocrine Tumor Grade 2 trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05111509, a Early Phase 1 study of Neuroendocrine Tumor Grade 2 and Neuroendocrine Tumor Grade 1, is active but no longer recruiting, sponsored by Yusuf Menda.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a first in man study to determine if \[203Pb\]VMT-α-NET identifies neuroendocrine tumors with SPECT/CT. This is the first step to testing \[212Pb\]-based alpha radiation therapy in neuroendocrine therapy.
Conditions Studied
Interventions
- DRUG [203Pb]VMT-α-NET
- DEVICE SPECT/CT
Study Locations (1)
Iowa
- The University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-08-22 |
| Est. Completion | 2026-06-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05111509
The ClinicalTrials.gov registry entry for NCT05111509 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 71-participant average among 3 other Neuroendocrine Tumor Grade 2 trials with a reported enrollment target (72% lower). The listed sponsor is Yusuf Menda, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neuroendocrine Tumor Grade 2 appearing as the primary indexed condition, and to 2 interventions - of which [203Pb]VMT-α-NET is the first listed.
NCT05111509 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT05111509 about?
NCT05111509 is a clinical study titled "A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent". This is a first in man study to determine if \[203Pb\]VMT-α-NET identifies neuroendocrine tumors with SPECT/CT. This is the first step to testing \[212Pb\]-based alpha radiation therapy in neuroendocrine therapy.
What is the current status of trial NCT05111509?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2022-08-22. Estimated completion is 2026-06-30.
What conditions does trial NCT05111509 study?
This clinical trial studies the following conditions: Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor Grade 1.
What interventions are being tested in trial NCT05111509?
The interventions under investigation include: [203Pb]VMT-α-NET (DRUG), SPECT/CT (DEVICE).
Who is sponsoring clinical trial NCT05111509?
This trial is sponsored by Yusuf Menda, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05111509 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumor Grade 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.